Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
-
REGULATORY LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
-
REGULATORY MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
-
ORGANIZATION Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
-
BUSINESS FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med
June 12, 2023
-
BUSINESS AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
-
REGULATORY Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
-
REGULATORY Sumitomo to Urge Switch from Noritren over Carcinogen Risks, but Continues Shipments
June 8, 2023
-
REGULATORY Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
-
REGULATORY Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
-
ORGANIZATION Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
-
BUSINESS Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
-
REGULATORY Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
-
REGULATORY Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
-
BUSINESS Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
-
BUSINESS Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
-
BUSINESS AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
-
REGULATORY Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
-
REGULATORY MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
-
BUSINESS Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…